Industry corner: Early drug development: Access to innovative oncology medicines in Europe

Annals of Oncology

Volumn 27, Issue 2, 2016, Pages 353-356

  Bergmann, L ^a   Enzmann, H ^b   Thirstrup, S ^c   Schweim, J K ^d   Widera, I ^e   Zwierzina, H ^f  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Federal Institute for Drugs and Medical Devices (BfArM)   (Germany)

^c NDA Advisory Services Ltd   (United Kingdom)

^d Law Office   (Germany)

^e PFIZER INC   (United States)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BUDGET; CONFIDENTIALITY; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG INDUSTRY; DRUG MARKETING; FEASIBILITY STUDY; GERMANY; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; HUMAN; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE PRICING; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; RISK BENEFIT ANALYSIS; BIOMEDICAL TECHNOLOGY ASSESSMENT; NEOPLASMS;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84961664632     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv547     Document Type: Editorial

References (8)

1. Bergmann L, Enzmann H, Broich K et al. Actual developments in European regulatory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe? Ann Oncol 2013; 25: 303-306.
2. Boyle P, Levin B. WHO World Cancer Report. 2008.
3. WHO GLOBOCAN PROJECT 2012 - Estimated Cancer Incidence, Mortality and Prevalence worldwide in 2012. n.d.
4. Stewart BW, Wild CP. WHO World Cancer Report. 2014.
5. Fischer KE, Stargardt T. Early benefit assessment of pharmaceuticals in Germany:manufacturers' expectations versus the Federal Joint Committee's decisions. Med Decis Making 2014; 34(8): 1030-1047.
6. European Medicines Agency (EMA). EMA-HTA Workshop Report: Bringing together stakeholders for early dialogue in medicines development. London, 2013.
7. European Medicines Agency (EMA). Best Practice Guidance for Pilot EMA HTA Parallel Scientific Advice Procedures. vol. 44. 2014.
8. European Medicines Agency (EMA). Scientific advice and protocol assistance, Parallel scientific advice with health-technology-assessment bodies n.d. http://www. ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000049. jsp&mid=WC0b01ac05800229b9 (14 June 2015, date last accessed).